Stocktoria

Editas Medicine, Inc. EDIT

Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-02-03
Chart by TradingView
1/9
Piotroski F — financial health
-29.91
Altman Z″ — distress risk · distress
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$40.5M$32.3M$78.1M$19.7M$25.5M
Operating income-$160.0M-$251.2M-$169.2M-$225.9M-$193.1M
Net income-$160.1M-$237.1M-$153.2M-$220.4M-$192.5M
Operating cash flow-$165.2M-$210.3M-$132.2M-$177.3M-$163.8M
Free cash flow-$165.8M-$219.1M-$136.9M-$181.5M-$171.8M
Total assets$186.5M$341.6M$499.2M$514.3M$677.5M
Total liabilities$159.2M$207.3M$150.1M$153.6M$123.8M
Shareholders' equity$27.3M$134.3M$349.1M$360.7M$553.6M
Ratios
Operating margin-394.9%-777.2%-216.6%-1146.3%-756.1%
Net margin-395.0%-733.7%-196.1%-1118.3%-753.6%
FCF margin-409.3%-678.1%-175.2%-920.6%-672.5%
Return on assets-85.8%-69.4%-30.7%-42.9%-28.4%
Return on equity-586.6%-176.6%-43.9%-61.1%-34.8%
Debt / equity1.96×0.39×0.00×
Current ratio3.543.755.395.9410.82
Revenue growth25.4%-58.6%296.3%-22.8%-71.8%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC3,972,160$9.8M
Point72 Asset Management, L.P.116,995$288,978

Why these scores methodology →

Piotroski F-score: 1/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: -29.91 (distress)

  • Working capital / assets 0.631
  • Retained earnings / assets -8.73
  • EBIT / assets -0.858
  • Equity / liabilities 0.171

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001650664 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.